Table 2. A summary of donors and cancer diagnoses included in the collection (status as of May 12, 2021).
| Diagnosis | Sex distribution | Average age | Average samples (range) | Clinical information |
|---|---|---|---|---|
| Breast cancer (ICD-10 C50) |
F– 99% (n = 921) M– 1% (n = 12) |
60 y ± 13 64 y ± 8 |
13 (7–32) | • Mastectomy– 42% (n = 391) • BCT– 53% (n = 494) • Non-specified* – 5% (n = 48) |
| Colorectal cancer (ICD-10 C18 –C21) |
F– 45% (n = 174) M –55% (n = 209) |
66 y ± 12 67 y ± 10 |
16 (7–27) | |
| Liver metastasis (colorectal cancer) (ICD-10 C78.7) |
M– 86% (n = 11) F– 14% (n = 3) |
65 y ± 11 66 ± 4 |
11 (7–15) | |
| Prostate cancer (ICD-10 C61) |
M– 100% (n = 221) | 65 y ± 7 | 15 (7–19) | Gleason score: • 3+2–0.5% (n = 1) • 3+3–16% (n = 35) • 3+4–28% (n = 61) • 4+3–28% (n = 61) • 4+4–2% (n = 5) • 4+4+5–0.5% (n = 2) • 4+5–1% (n = 3) • Non-specified* – 24% (n = 53) |
| Bladder cancer (ICD-10 C67) |
F– 21% (n = 17) M– 79% (n = 64) |
68 y ± 8 69 y ± 9 |
12 (7–17) | • TURBT– 47% (n = 38) • Cystectomy– 53% (n = 43) |
| Pancreatic cancer (exocrine, ICD-10 C25) |
Female– 47% (n = 7) Male– 53% (n = 8) |
68 y ± 6 66 y ± 9 |
10 (8–11) | |
| Control group** | Male– 100% (n = 64) | 71 ± 5 | 7 (6–12) |
F–female; M–male; *—information not yet available and incorporated in our database; y–years; BCT–Breast Conservative Therapy. ICD codes: C50, Malignant neoplasm of breast; C18, Malignant neoplasm of colon; C19, Malignant neoplasm of rectosigmoid junction; C20, Malignant neoplasm of rectum; C21, Malignant neoplasm of anus and anal canal; C78.7, Secondary malignant neoplasm of liver and intrahepatic bile duct; C61, Malignant neoplasm of prostate; C67, Malignant neoplasm of bladder; C25, Malignant neoplasm of pancreas; TURBT–Transurethral Resection of Bladder Tumor.
**—Healthy male cohort ≥ 65 years old recruited as controls for the male patients with prostate and colorectal cancer for whom the white blood cell fractions were sorted by FACS to study loss of chromosome Y.